Simplifying self-medication: SCHOTT Pharma expands cartridge production in China and Hungary
Thursday, September 22, 2022, Mainz, Germany
- The double-digit million Euro investment is designed to significantly increase the production capacities for pharmaceutical cartridges in Hungary and China.
- Cartridges are used to store and administer drugs, such as insulin, GLP-1, or growth hormones, which can be self-injected with the help of an auto-injector.
SCHOTT Pharma cartridges are compatible with a wide range of devices to enable safe and easy-to-use drug delivery in highly accurate doses. As a non-sterile variant, the cartridges are available in 1-20 ml formats and delivered in a tray with optional dividers. The investment will further allow the company to advance its state-of-the-art forming technology and 100% on-line inspection systems.
About SCHOTT Pharma
SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world – because human health matters. The portfolio comprises drug containment and delivery solutions for injectable drugs ranging from prefillable glass and polymer syringes, to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 65 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 900 patents and technologies developed in-house, a state-of-the-art R&D center in Switzerland, and around 130 employees in R&D, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA, headquartered in Mainz, Germany, is part of SCHOTT AG that is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,700 customers including the top 30 leading pharma manufacturers for injectable drugs and generated sales of EUR 650 million in the fiscal year 2021.